Kidney Week 2026 Early Program On-Demand - Onconephrology in 2026: New Therapies, Opportunities, and Challenges
Availability
On-Demand
Contains (12)
Plasma Cell Dyscrasias and Engineered Cellular Therapy: Is a Cure in Sight?
Update on Paraproteinemia and Kidney Pathologies: Monoclonal vs. Monotypic
Novel Radioligand Therapies and Nephrotoxicity
Is It Real? AKI and Electrolyte Disturbances in Cancer and Novel Targeted Therapies
Kidney Transplant Onconephrology: Immunotherapies, Engineered Cellular Therapies, and Management of Post-Transplant Lymphoproliferative Disorder
Case-Based Debates in Onconephrology 1: To Transplant or Not to Transplant? Selection and Evaluation for Kidney Transplantation in Patients with Solid and Hematologic Cancers
Thrombotic Microangiopathy in Patients with Cancer: Decoding the Role of Complement Regulation and Inhibition
Pathology Case-Based Review: Paraneoplastic Glomerular Diseases
What's New? Immune Checkpoint Inhibitors: Biomarkers, Imaging, and Rechallenge
Too Much or Too Little? Individualizing GFR Assessments and Multidisciplinary Dose Adjustment of Anticancer Therapies in Patients with CKD and ESKD
Can We Predict and Prevent AKI Caused by Cytotoxic Cancer Therapies? Risk Scores, Nephroprotective Strategies, and Rescue Treatments
Case-Based Debates in Onconephrology 2: Kidney Biopsy Should Be Performed in Patients with Immune Checkpoint Inhibitor-Induced AKI; Erythropoietin-Stimulating Agents Should Be Avoided in Patients with Cancer
Did you join us in Denver this year?  On-Demand session recordings are already available in your Early Program course. 

Click here to go to your course list where you can access the Early Program, view lecture recordings, share your feedback, and claim continuing education credit by December 17, 2026.

Note: Login required.
Click each header to expand and learn more.